U.S. markets closed

Gamida Cell Ltd. (GMDA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.3300+0.0200 (+6.45%)
At close: 04:00PM EST
0.3326 +0.00 (+0.79%)
After hours: 07:35PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Long-term KST

Long-term KST

Previous Close0.3100
Bid0.3302 x 1300
Ask0.3327 x 1000
Day's Range0.2999 - 0.3344
52 Week Range0.2200 - 2.5100
Avg. Volume1,807,306
Market Cap43.771M
Beta (5Y Monthly)1.59
PE Ratio (TTM)N/A
EPS (TTM)-0.8200
Earnings DateNov 14, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for GMDA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Gamida Cell Ltd.
    Analyst Report: AbbVie Inc.AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • GlobeNewswire

    Gamida Cell to Host Virtual Thought Leader Fireside Chat on December 4, 2023

    BOSTON, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, is hosting a virtual fireside chat with thought leader Gary Schiller, MD, FACP, Professor of Medicine and Director of the Hematological Malignancy & Stem Cell Transplant Program at the David Geffen School of Medicine at University of California – Los Angeles. Dr. Schiller will discuss his experience working with patients in need of allogeneic stem ce

  • GlobeNewswire

    Gamida Cell to Present Corporate Highlights at the Piper Sandler 35th Annual Healthcare Conference

    BOSTON, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that its management team will present corporate highlights at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, NY. Presentation Details Format:Fireside ChatDate/Time:Tuesday, November 28, 2023 at 11:00 –11:25 AM ETWebcast:Click here. The Gamida Cell management team will be available for one-on-one meetings dur

  • Insider Monkey

    Gamida Cell Ltd. (NASDAQ:GMDA) Q3 2023 Earnings Call Transcript

    Gamida Cell Ltd. (NASDAQ:GMDA) Q3 2023 Earnings Call Transcript November 14, 2023 Gamida Cell Ltd. beats earnings expectations. Reported EPS is $-0.01, expectations were $-0.15. Operator: Ladies and gentlemen, thank you for standing by. Welcome to Gamida Cell’s Conference Call for Third Quarter 2023 Financial Results. My name is Chris, and I’ll be your operator […]